Key information

🔎 Fund Overview

Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier for a variety of wound types, and the Affinity, Novachor and NuShield wound coverings to address a variety of wound sizes and types. Its sports medicine products include NuShield for surgical application in soft tissue repairs, and Affinity, Novachor and PuraPly AM for management of open wounds in the surgical setting. It offers its products to a range of healthcare customers, including hospitals, wound care centers and physician offices.